Table 7 Clinicopathological parameters analysis according to rs1966265 genetic polymorphism in breast cancer patients
Clinicopathological parameters | rs1966265(N = 90) | ||||
|---|---|---|---|---|---|
GG | AG &AA | OR | 95%CI | P | |
T-status,n(%) | |||||
  ≤ T2 | 3(3.3) | 3(3.3) |  |  |  |
  > T2 | 17(18.9) | 67(74.4) | 3.941 | 0.730–21.284 | 0.111 |
N-status,n(%) | |||||
 N0+ N1 | 15(6.7) | 55(61.1) |  |  |  |
 N2+ N3 | 5(5.6) | 15(16.7) | 0.818 | 0.256–2.615 | 0.735 |
Tumor grade | |||||
 GradeII | 8(8.9) | 26(28.9) |  |  |  |
 GradeIII | 12(13.3) | 44(48.9) | 1.128 | 0.408–3.121 | 0.816 |
ER | |||||
 positive | 16(17.8) | 46(51.1) |  |  |  |
 negative | 4(4.4) | 24(26.7) | 2.087 | 0.628–6.941 | 0.230 |
PR | |||||
 positive | 13(14.4) | 38(42.2) |  |  |  |
 negative | 7(7.8) | 32(35.6) | 1.564 | 0.557–4.390 | 0.396 |
Her2-neu stastus | |||||
 positive | 7(7.8) | 25(27.8) |  |  |  |
 negative | 13(14.4) | 45(50.0) | 0.969 | 0.342–2.744 | 0.953 |
TNBC | |||||
 Yes | 3(3.3) | 13(14.4) |  |  |  |
 No | 17(18.9) | 57(63.3) | 1.292 | 0.328–5.072 | 0.713 |
P63 | |||||
 positive | 2(2.2) | 1(1.1) |  |  |  |
 negative | 18(20.0) | 69(76.7) | 7.667 | 0.658–89.367 | 0.104 |
Ki-67 | |||||
 positive | 3(3.3) | 25(27.8) |  |  |  |
 negative | 17(18.9) | 45(50.0) | 0.318 | 0.085–1.190 | 0.089 |